Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss

NCT02822482 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped futilty of the treatment

Conditions

Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG: Copanlisib
DRUG: Cetuximab

Sponsor

UNICANCER